{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:29:52Z","timestamp":1723595392447},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,13]]},"DOI":"10.7759\/cureus.66785","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T16:32:16Z","timestamp":1723566736000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Benefits of Octreotide for Managing Persistent Gastrointestinal Fluid Loss in Malignant Small Bowel Obstruction: A Case Report and Literature Review"],"prefix":"10.7759","author":[{"given":"Chalothorn","family":"Wannaphut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Landon A","family":"Kozai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narathorn","family":"Kulthamrongsri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chutawat","family":"Kookanok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanprapit","family":"Noree","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamonluk","family":"Rodsom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekamol","family":"Tantisattamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jared","family":"Acoba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S29297","article-title":"Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution","volume":"4","author":"Tuca A","year":"2012","unstructured":"Tuca A, Guell E, Martinez-Losada E, Codorniu N. Malignant bowel obstruction in advanced cancer patients: epidemiology, management, and factors influencing spontaneous resolution. Cancer Manag Res. 2012, 4:159-69. 10.2147\/CMAR.S29297","journal-title":"Cancer Manag Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/s0736-4679(98)00123-1","article-title":"Severe metabolic alkalosis due to baking soda ingestion: case reports of two patients with unsuspected antacid overdose","volume":"17","author":"Fitzgibbons LJ","year":"1999","unstructured":"Fitzgibbons LJ, Snoey ER. Severe metabolic alkalosis due to baking soda ingestion: case reports of two patients with unsuspected antacid overdose. J Emerg Med. 1999, 17:57-61. 10.1016\/s0736-4679(98)00123-1","journal-title":"J Emerg Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/s0196-0644(88)80781-9","article-title":"Severe metabolic alkalosis in the emergency department","volume":"17","author":"Mennen M","year":"1988","unstructured":"Mennen M, Slovid CM. Severe metabolic alkalosis in the emergency department. Ann Emerg Med. 1988, 17:354-7. 10.1016\/s0196-0644(88)80781-9","journal-title":"Ann Emerg Med"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.12.016","article-title":"Metabolic alkalosis pathogenesis, diagnosis, and treatment: Core Curriculum 2022","volume":"80","author":"Do C","year":"2022","unstructured":"Do C, Vasquez PC, Soleimani M. Metabolic alkalosis pathogenesis, diagnosis, and treatment: Core Curriculum 2022. Am J Kidney Dis. 2022, 80:536-51. 10.1053\/j.ajkd.2021.12.016","journal-title":"Am J Kidney Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2010.05.002","article-title":"Octreotide","volume":"40","author":"Murphy E","year":"2010","unstructured":"Murphy E, Prommer EE, Mihalyo M, Wilcock A. Octreotide. J Pain Symptom Manage. 2010, 40:142-8. 10.1016\/j.jpainsymman.2010.05.002","journal-title":"J Pain Symptom Manage"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.amsu.2015.07.018","article-title":"Management of intestinal obstruction in advanced malignancy","volume":"4","author":"Ferguson HJ","year":"2015","unstructured":"Ferguson HJ, Ferguson CI, Speakman J, Ismail T. Management of intestinal obstruction in advanced malignancy. Ann Med Surg (Lond). 2015, 4:264-70. 10.1016\/j.amsu.2015.07.018","journal-title":"Ann Med Surg (Lond)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1996.0154","article-title":"Octreotide in the management of bowel obstruction in terminal ovarian cancer","volume":"61","author":"Mangili G","year":"1996","unstructured":"Mangili G, Franchi M, Mariani A, et al.. Octreotide in the management of bowel obstruction in terminal ovarian cancer. Gynecol Oncol. 1996, 61:345-8. 10.1006\/gyno.1996.0154","journal-title":"Gynecol Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-010-1009-4","article-title":"Can malignant bowel obstruction in advanced cancer patients be treated at home?","volume":"19","author":"Porzio G","year":"2011","unstructured":"Porzio G, Aielli F, Verna L, Galletti B, Shoja E Razavi G, Ficorella C. Can malignant bowel obstruction in advanced cancer patients be treated at home?. Support Care Cancer. 2011, 19:431-3. 10.1007\/s00520-010-1009-4","journal-title":"Support Care Cancer"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06438-9","article-title":"Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update","volume":"29","author":"Davis M","year":"2021","unstructured":"Davis M, Hui D, Davies A, et al.. Medical management of malignant bowel obstruction in patients with advanced cancer: 2021 MASCC guideline update. Support Care Cancer. 2021, 29:8089-96. 10.1007\/s00520-021-06438-9","journal-title":"Support Care Cancer"},{"key":"ref10","article-title":"Effect of clonidine on gastrointestinal transit time","volume":"45","author":"Mann NS","year":"1998","unstructured":"Mann NS, Shinkle JM. Effect of clonidine on gastrointestinal transit time. Hepatogastroenterology. 1998, 45:1023-5.","journal-title":"Hepatogastroenterology"},{"key":"ref11","article-title":"Clonidine prolongs human small intestine transit time: use of the lactulose-breath hydrogen test","volume":"84","author":"Rubinoff MJ","year":"1989","unstructured":"Rubinoff MJ, Piccione PR, Holt PR. Clonidine prolongs human small intestine transit time: use of the lactulose-breath hydrogen test. Am J Gastroenterol. 1989, 84:372-4.","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2001.281.6.G1468","article-title":"Effects of an \u03b12-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans","volume":"281","author":"Viramontes BE","year":"2001","unstructured":"Viramontes BE, Malcolm A, Camilleri M, Szarka LA, McKinzie S, Burton DD, Zinsmeister AR. Effects of an \u03b12-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol Gastrointest Liver Physiol. 2001, 281:G1468-76. 10.1152\/ajpgi.2001.281.6.G1468","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1989.tb00234.x","article-title":"The effect of a new selective a2-adrenoreceptor antagonist, idazoxan, and the agonist, clonidine, on fasting antroduodenal motility in healthy volunteers","volume":"3","author":"Gregersen H","year":"1989","unstructured":"Gregersen H, Kraglund K, Rittig S, T\u00f8ttrup A. The effect of a new selective a2-adrenoreceptor antagonist, idazoxan, and the agonist, clonidine, on fasting antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther. 1989, 3:435-43. 10.1111\/j.1365-2036.1989.tb00234.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1M658","article-title":"Crofelemer, a novel agent for treatment of secretory diarrhea","volume":"44","author":"Crutchley RD","year":"2010","unstructured":"Crutchley RD, Miller J, Garey KW. Crofelemer, a novel agent for treatment of secretory diarrhea. Ann Pharmacother. 2010, 44:878-84. 10.1345\/aph.1M658","journal-title":"Ann Pharmacother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1586\/egh.11.87","article-title":"Crofelemer for the treatment of secretory diarrhea","volume":"6","author":"Cottreau J","year":"2012","unstructured":"Cottreau J, Tucker A, Crutchley R, Garey KW. Crofelemer for the treatment of secretory diarrhea. Expert Rev Gastroenterol Hepatol. 2012, 6:17-23. 10.1586\/egh.11.87","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/238451-clinical-benefits-of-octreotide-for-managing-persistent-gastrointestinal-fluid-loss-in-malignant-small-bowel-obstruction-a-case-report-and-literature-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T16:32:19Z","timestamp":1723566739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/238451-clinical-benefits-of-octreotide-for-managing-persistent-gastrointestinal-fluid-loss-in-malignant-small-bowel-obstruction-a-case-report-and-literature-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.66785","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,13]]}}}